MENU

News | CellFree Sciences

header jp

header en

News

Now on Launching : NanoDisc BD Kit

Category: Announcements Created: Sunday, 17 September 2023

Difficult to express 2

 

We, CellFree Sciences Co., Ltd. launched "NanoDisc BD Kit", now !!

 

              NanoDisc

 

This new kit has following features ;

  • WEPRO7240ND, a wheat germ extract optimized for Nanodisc synthesis
  • With the Bi-Layer & Dialysis (BD) reaction, which has a proven track record in proteoliposome synthesis
  • A new method for NanoDisc synthesis (patent pending) that co-expresses mRNA for MSP protein and mRNA for the target membrane protein.

This kit enables high-quality and high-efficiency synthesis of NanoDisc for membrane proteins that have been difficult to

express in the past, and is hoped to further advance research on functional and structural analysis.

 

 

                          Claudin4 3

 

=====================Product Information ==============================

-Catalogue Number : CFS-CNDE-BD

-Product Name NanoDisc BD Kit

-SIZE : 5 reaction with 2.0 mL reaction scales of Bi-layer & Dialysis (BD) reaction

-Stock Temperature : -80℃

-List Price : $4,000.- /kit

-Specification : Claudin 4 can be synthesized as NanoDisc with more than 100ug per

 Bi-Layer & Dialysis reaction.

====================================================================

Please contact to us and to our sales agents in your region, now.

 

 

Campaign "Launching for NanoDisc BD Kit" !!

Category: Announcements Created: Sunday, 17 September 2023

 

Campaign !!  

“launching for NanoDisc BD Kit

 

Now, we are offering a 25% off campaign for try to use NanoDisc BD Kit until the end of this December.

 

NanoDisc

 

$4,000/kit to $3,000/ kit !!

And also, if you try Wheat germ Cell Free Protein expression system for the fist time…………

with the purchase of the NanoDisc BD kit, you will receive a free Premium PLUS Expression Kit to confirm       of your target membrane proteins expression.

Please contact to us and to our sales agents in your region, now.

 

 

 

 

Campaign : Special Offer until September 30, 2022: Synthesis Services for mono-biotinylated Proteins

Category: Announcements Created: Friday, 01 July 2022

Special Offer until September 30, 2022:

Synthesis Services for mono-biotinylated Proteins

Biotinylation of proteins is one of the most commonly use methods for working with labeled proteins. Based on the very strong interaction between biotin and Streptavidin, biotinylated proteins can be easily used in different assay formats. Our wheat germ cell-free system allows us to easily prepare mono-biotinylated proteins during translation reactions. Find out more on our approach and services for preparing mono-biotinylated proteins on our homepage:

https://www.cfsciences.com/eg/protein-biotinylation-services

Make use of our Special Offer on every order received until September 30, 2022, for using our services to prepare a mono-biotinylated protein. This offer includes:

  • Protein expression reaction on 6 ml bilayer format*,
  • Protein purification using His- or GST-tag**,
  • Protein QC by SDS-PAGE,
  • Confirmation of protein biotinylation by HABA Test***,
  • Protein stock provided in elution buffer plus glycerol****,
  • Negative control reaction without template can be provided.

*CFS can use different biotin concentrations in the translation reaction depending on how the biotinylated protein will be used.

**His- or GST-tag are normally placed on C terminus.

***Using Pierce™ Biotin Quantitation Kit to determine biotinylation level.

****Buffer exchange possible on customer request.

Service fee: JPY 240,000 (EURO 1,700, USD 2,000), shipping costs not included in service fee.

CFS will provide expression vector pEU-E01-bls-TEV-MCS free of charge to enable customers to prepare their own expression template. Otherwise, CFS can arrange for template preparation by gene synthesis at a fee of JPY 200,000 (EURO 1,400; USD 1,600).

Turnaround time: 4 weeks upon availability of expression vector; turnaround time for gene synthesis and vector preparation not included.

No foreseeing statements can be made about the expected protein yields.

Contact us for more information and ordering at: This email address is being protected from spambots. You need JavaScript enabled to view it..

 

CellFree Sciences Co., Ltd.

 

New Year Campaign for Custom Synthesis Service is now on !!

Category: Announcements Created: Wednesday, 26 January 2022

We started New Year Campaign for Protein Syntehsis Service.

So, it is good time to try Wheat Germ Protein Systesis technology for your taget proteins, now.

 

Please access to "Campaign Page" on this Site, now.

 

CellFree Sciences Co., Ltd.

 

Season Greetings From CellFree Sciences

Category: Announcements Created: Tuesday, 21 December 2021

 

Season Greetings

From CellFree Sciences!

 

2022 Season Greeting

 

Our way of saying thank you.

 

With the year ending, we want to thank you for working together with CellFree Sciences and express our sincere wishes for the Seasons and a Happy, Healthy and Prosperous New Year!

 


This year had been complicated for all of us with life been very much dominated by the ongoing COVID-19 pandemic and the suffering it had broad to many people worldwide. But there is also hope in the times of the pandemic, which showed more than ever the importance of life sciences and the contribution we can make to bring the pandemic to an end. It fills us with pride that also our wheat germ cell-free expression system is used in the response to the COVID-19 pandemic to prepare viral proteins for research and the development and production of diagnostic products now available on the Japanese market. CellFree Sciences is committed to keep on supporting medical research and to work for better solutions in global health.

 


CellFree Sciences will start into 2022 with new assay service by using protein array for protein-protein interaction assay and "campaign for custom synthesis service" .

 


We all at CellFree Sciences are looking forward to being at your service again in 2022 supporting your important projects with our reagents and services. Please contact us and let us know about your needs and requirements. It is our commitment to work for our customers and partners to make your projects successful.

 


With all the very best wishes for you and yours for a better New Year 2022 from all of us at CellFree Sciences!

 

 

Changing procedures for kit manuals from May 10, 2021

Category: Announcements Created: Wednesday, 28 April 2021

Thank you very much indeed for working together with CellFree Sciences and using our cell-free protein expression system in your work.

CellFree Sciences wants to contribute to the global efforts to reduce paper usage. Therefore, we have decided to ship from May 10, 2021, all our reagents and kits without a printed manual.

 

All our manuals are available for download on our homepage and directions on how to access the manuals and other product related information will be attached to each shipment for guiding our customers.

 

If you have any questions on the use of our products or how to access the product manuals, please contact us.

We are happy to assist you and to send you a PDF version of our manuals.

 

Thank you for your understanding and support! We hope our customers will appreciate our efforts to reduce paper use by switching to paperless notes or keeping the number of printed pages to a minimum.

The GHIT Fund of Japan continues their support for the development of a malaria transmission-blocking vaccine.

Category: Announcements Created: Thursday, 01 April 2021

The GHIT Fund of Japan announced on March 31, 2021, their new investments to support global R&D projects for neglected tropical diseases. This includes new funding for a First-In-Human Trial of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1.

 

CellFree Sciences is most grateful for the continuous support given by the GHIT Fund for the development of an AnAPN1-based malaria transmission-blocking vaccine! In a project led by Prof. Rhoel Dinglasan at the University of Florida, we had been working together for several years on the development of an optimized antigen focusing on the transmission-blocking domain in the AnAPN1 protein. With the new GHIT funding, we will now move this new antigen to clinical development in Gabon.

 

We are looking forward to working together with Ajinomoto Bio-Pharma Services, GeneDesign, the Centre de Recherches Médicales de Lambaréné (CERMEL), University of Tübingen and The University of Florida to make this important project successful. It is our hope that this vaccine will in the future contribute to better malaria control and eradication.

 

Link to GHIT press release:

 

Project description on GHIT Webpage:

 

 

 

CellFree Sciences responded to new State of Emergency in Japan

Category: Announcements Created: Wednesday, 03 February 2021

On February 2nd, 2021, the Government of Japan extended the Coronavirus State of Emergency for Tokyo, Osaka and eight other prefectures for one more month. The new measures will be in effect until March 7th, 2021 according to the present government plans.

 

CellFree Sciences is fully supporting the actions of the Japanese Government! We have therefore extended also our own actions to protect our staff following government directions and to make our contribution to help stopping the further spread of the virus.

 

We will keep on making best efforts to support our customers also during the State of Emergency.

 

All orders will be processed as usual as we know about the importance of the work our customers are doing.

 

Please contact us for more information.

A set of 1118 human transcription factors was made by our expression system to study side effects of "thalidmide"

Category: Announcements Created: Friday, 22 January 2021

A joint effort by several universities and research institutes in Japan, including our strategic technology partners Dr. Satoshi Yamanaka and Professor Tatsuya Sawasaki at the Proteoscience Center of Ehime University, conducted a comprehensive study using a human protein array comprising 1,118 human transcription factors produced in our wheat germ cell-free protein expression system. Screening those proteins led to the discovery that thalidomide and its metabolite 5‐hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF.

 

Thalidmide was originally used as a sleeping drug for pregnant women but had caused terrible side effects. Later it was found that Thalidmide and its derivatives are potent drugs for treating leprosy and multiple myeloma. These are highly effective drugs that are now sold for about 1 trillion yen per year in the world for treatment of blood cancers such as multiple myeloma. However, these drugs require a strict safety management to avoid teratomas. The new finding reported here will help to develop better thalidmide derivatives that could avoid any risk for teratoma formation.

 

For details, please click here.

 

Please click here for a paper on this research.

 

 

CellFree Sciences responded to new State of Emergency in Japan

Category: Announcements Created: Friday, 08 January 2021

On January 7th, 2021, the Government of Japan declared the State of Emergency for Tokyo and the three neighboring prefectures of Kanagawa, Saitama and Chiba in response to claiming numbers of COVID-19 cases in the area. The new measures will be in effect until February 7th, 2021 according to the present government plans.

 

CellFree Sciences is fully supporting the actions of the Japanese Government! We have taken actions to protect our staff following government directions and to make our contribution to help stopping the further spread of the virus.

 

We will make best efforts to support our customers also during the State of Emergency. 

 

All orders will be processed as usual as we know about the importance of the work our customers are doing.

 

Please contact us for more information.

Copyright © CellFree Sciences Co.,Ltd. All Rights Reserved. [login]

We use cookies to ensure you get the best experience. By using our website you agree to our Cookie Policy.